The China CDMO market was valued at USD 23.77 Billion in 2025 and is expected to grow at a CAGR of 11.70%, reaching USD 71.87 Billion by 2035. The market is driven by the robust manufacturing infrastructure, cost-efficient operations, and growing regulatory harmonization across the region. Additionally, opportunities are expanding with the rise in biologics demand, growth in advanced therapies like cell and gene treatments, and a surge in international licensing and tech transfer deals, accelerating China's role in global pharmaceutical supply chains.
Base Year
Historical Period
Forecast Period
Licensing-driven outsourcing is fueling biologics CDMO expansion in oncology, evidenced by USD 44 billion in partnerships.
The market growth is driven by rising regulatory segment manufacturing approvals in cities like Shanghai, that are enhancing flexibility and service depth for biologics production.
The market value is impacted by increasing geopolitical tensions, that are prompting resilience strategies, motivating domestic investment and protective policy frameworks.
Compound Annual Growth Rate
11.7%
Value in USD Billion
2026-2035
*this image is indicative*
In China, the market plays a pivotal role in accelerating biopharma innovation by offering scalable drug development and manufacturing solutions. With robust government backing, low-cost yet high-tech facilities, and strong integration into global supply chains, CDMOs support both domestic drug developers and multinational pharmaceutical companies, enhancing China’s competitiveness in the global healthcare ecosystem. The market is expected to grow at a CAGR of 11.70% during the forecast period of 2026-2035 and attain a market value of USD 71.87 Billion by 2035.
Strategic Collaborations to Elevate CDMO Market Innovation in China
Rising demand for advanced therapy platforms and regulatory support for ATMPs is driving collaboration in China’s CDMO ecosystem. For instance, in May 2025, Porton Advanced partnered with Hualong Biological to deliver end-to-end CDMO services, including process optimization, GMP manufacturing, and regulatory submission, for a novel Multi-Activated T Cell (MATC) therapy. This strategic alliance accelerates clinical progression and deepens China’s capacity in next-gen ATMP manufacturing, positioning the country for leadership in cell-therapy outsourcing at the global level.
Major market trends include regulatory streamlining and strategic expansions by the key players.
Large-Scale CDMO Facility Investments to Boost China CDMO Market Value
Surging demand for vaccines, therapeutic proteins, and ADCs is driving CDMOs to aggressively invest in production infrastructure. For instance, in June 2025, WuXi Biologics broke ground on a new microbial manufacturing plant in Chengdu, featuring China’s first dual‑chamber lyophilization line and 15,000 L fermenter, set to complete by 2026. This major facility expansion will significantly boost China’s bioproduction capabilities and help local CDMOs compete more effectively for global contracts.
Strategic Capacity Expansion to Meet Growing China CDMO Market Demand
The growing emphasis on regional diversity and integrated capability is prompting CDMO consolidation in China. For instance, in January 2025, Joinn Biologics completed its acquisition of Lonza’s biologics manufacturing plant in Guangzhou, taking over existing modular production lines, vial filling, and QC labs. This transaction enables Joinn to scale locally, reduce time-to-market for Chinese biotech clients, and strengthen its foothold in the Greater Bay Area, setting a model for other CDMOs expanding capacity through strategic asset acquisition.
Contract Manufacturing Organization to Lead the Market by Service Type
CRO activities in the service type segment are expanding at a CAGR of 10.9%, while CMO services are growing even faster at 11.9%, underscoring the scale and complexity of oncology outsourcing. This growth is supported by strategic licensing deals and manufacturing reforms tailored to cancer therapeutics. In contrast, segments such as infectious and metabolic diseases are expanding steadily but remain secondary due to their lower development intensity and outsourcing depth.
The key features of the market report comprise grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Vetter Pharma‑Fertigung GmbH & Co. KG is headquartered in Ravensburg, Germany, founded in 1950. It operates a Shanghai office and specializes in aseptic filling and packaging services for injectables. Vetter’s advanced clinical-to-commercial capacity supports Chinese biopharma firms requiring sterile manufacturing and accelerates local market inclusion. Its Asia-Pacific presence since 2021 underscores strategic alignment with China’s growing reliance on outsourced sterile drug production.
Recipharm AB, founded 1995 and based in Sweden, offers biologics, sterile, and oral solids CDMO services. In 2024, Recipharm initiated collaborations with Chinese biosimilars ventures to co-develop scale-up capacity. Its flexible manufacturing platforms and local regulatory compliance position it as a strong partner supporting China’s mid-sized biotech pipeline development.
Boehringer Ingelheim, founded 1885 in Germany, operates a Shanghai BioXcellence site that recently gained approval for segmented manufacturing under NMPA reform. Its mammalian cell culture capabilities and regulatory-aligned Shanghai operations enable stage-specific drug development and commercial production, positioning BI as a key biologics CDMO supplier enhancing local capacity.
Patheon Pharma Services (Thermo Fisher Scientific Inc.), headquartered in Waltham, MA, has expanded its reach in China via regulatory support and clinical logistics partnerships since 2023. Its integrated small- and large-molecule CDMO offerings, including fill/finish and regulatory filings, help Chinese biotech firms accelerate approvals and global launch, with growing facility activity in China.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Samsung Biologics Co., Ltd., Lonza Group, WuXi AppTec, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share